Gut Microbiome Shows Promise as Factory for Longevity-Promoting Compounds

A research team led by Howard Hughes Medical Institute Senior Group Leader Meng Wang explored how bacteria found in animal digestive tracts can be leveraged to produce compounds that support longevity in their hosts. The group, with its longstanding interest in understanding and applying longevity-promoting compounds, set out to move beyond discovery into practical applications. 

Their approach, described in a recent PLOS Biology paper, centered on colanic acid, a molecule produced naturally by certain gut bacteria and previously noted for its life-extending effects in organisms such as roundworms and fruit flies. Using this as a model, Wang and her team investigated whether they could boost the production of colanic acid using a targeted chemical intervention.

The team discovered that exposing bacteria to low doses of the antibiotic cephaloridine leads to an overproduction of colanic acids. Subsequent experiments showed that roundworms treated with cephaloridine-enriched bacteria exhibited increased lifespan. Taking the investigation a step further, the researchers applied the strategy to mice and found that oral administration of low doses of cephaloridine triggered gene expression changes in a segment of the gut bacterial genome responsible for synthesizing colanic acids. These molecular shifts brought about notable metabolic effects: male mice experienced rises in beneficial cholesterol and declines in harmful cholesterol, while female mice had reduced insulin levels.

One key advantage of this approach is that cephaloridine, when given orally, is not absorbed systemically. Its action is confined to the gut microbiome, meaning the animals received the desired microbiota-driven benefits without experiencing side effects or toxicity typically associated with antibiotic therapies.

The findings highlight a promising avenue for developing new drug strategies. Instead of designing drugs to act directly on the animal, researchers can target the host’s microbiota, encouraging them to generate metabolites that support healthy aging. The authors hope these results will influence how scientists think about drug design—shifting focus from traditional compounds acting on the body to those that modulate the gut microbiome.